Segment Information and Concentration of Business Risk (Tables)

6 Months Ended

Jun. 30, 2016

Segment Information and Concentration of Business Risk [Abstract]

Segment Information

The following table shows our segment revenue and loss from operations for the three and six months ended June 30, 2016 and June 30, 2015 (in thousands), respectively.

Three Months Ended June 30, 2016	Ionis Core			Akcea Therapeutics			Elimination of Intercompany Activity		Total
Revenue:
Research and development	$	22,455		$	—		$	—	$	22,455
Licensing and royalty		16,015			—			—		16,015
Total segment revenue	$	38,470		$	—			—	$	38,470
Loss from operations	$	(34,152	)	$	(14,805	)	$	30	$	(48,927	)

Three Months Ended June 30, 2015	Ionis Core		Akcea Therapeutics			Elimination of Intercompany Activity		Total
Revenue:
Research and development	$	119,658	$	—		$	—	$	119,658
Licensing and royalty		770		—			—		770
Total segment revenue	$	120,428	$	—			—	$	120,428
Income (loss) from operations	$	53,535	$	(8,919	)	$	30	$	44,646

Six Months Ended June 30, 2016	Ionis Core			Akcea Therapeutics			Elimination of Intercompany Activity		Total
Revenue:
Research and development	$	57,670		$	—		$	—	$	57,670
Licensing and royalty		17,675			—			—		17,675
Total segment revenue	$	75,345		$	—		$	—	$	75,345
Loss from operations	$	(72,790	)	$	(30,847	)	$	60	$	(103,577	)

Six Months Ended June 30, 2015	Ionis Core		Akcea Therapeutics			Elimination of Intercompany Activity		Total
Revenue:
Research and development	$	181,551	$	—		$	—	$	181,551
Licensing and royalty		1,461		—			—		1,461
Total segment revenue	$	183,012	$	—		$	—	$	183,012
Income (loss) from operations	$	51,210	$	(15,953	)	$	60	$	35,317

The following table shows our total assets by segment at June 30, 2016 and December 31, 2015 (in thousands), respectively.

Total Assets	Ionis Core		Akcea Therapeutics		Elimination of Intercompany Activity			Total
June 30, 2016	$	883,519	$	63,728	$	(136,138	)	$	811,109
December 31, 2015	$	995,852	$	66,306	$	(114,258	)	$	947,900

Revenue from Significant Partners

We have historically funded our operations from collaborations with corporate partners and a relatively small number of partners have accounted for a significant percentage of our revenue. Revenue from significant partners, which is defined as ten percent or more of our total revenue, was as follows:

	Three Months Ended June 30,				Six Months Ended June 30,
	2016		2015		2016		2015
Partner A		39 %		0 %		20 %		0 %
Partner B		25 %		15 %		41 %		31 %
Partner C		10 %		76 %		7 %		50 %
Partner D		5 %		4 %		9 %		11 %